Abstract: The present invention relates to use of an inhibitor of the renin-anglotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).
Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPIV can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
Abstract: The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.
Type:
Grant
Filed:
July 10, 2007
Date of Patent:
November 1, 2011
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Jochen Goerlitzer, Heiner Glombik, Eugen Falk, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Christian Stapper, Wolfgang Wendler
Abstract: The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.
Type:
Grant
Filed:
January 11, 2007
Date of Patent:
June 28, 2011
Assignees:
Aventis Pharma Deutschland GmbH, Sanofi-Aventis Deutschland GmbH
Inventors:
Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Thomas Boehme, Gerhard Hessler, Petra Stahl, Dirk Gretzke
Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPIV can be used to monitor platelet age and exposure to thrombiotic and cardiovascular diseases.
Abstract: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
Type:
Grant
Filed:
February 7, 2008
Date of Patent:
February 16, 2010
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Klaus Bosslet, Gerhard Seemann, Hans Harald Sedlacek, Bernhard Auerbach
Abstract: Peptides having bradykinin-antagonistic action are suitable for the production of pharmaceuticals for the prophylaxis and therapy of diseases in whose course an increased activity of matrix metalloproteinases is involved. These include diseases such as degenerative joint diseases, for example osteoarthrosis, spondylosis and chondroporosis after joint trauma or relatively long immobilization of a joint after meniscus or patella injuries or torn ligaments. The invention therefore relates to the use of a compound of the formula I, A-B-X-E-F-K-(D)-TIC-G-M-F?-I??(I) for the production of pharmaceuticals for the treatment of degenerative joint diseases, wherein A, B, X, E, F, K, (D)-TIC, G, M, F? and I are as defined herein.
Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.
Type:
Application
Filed:
September 14, 2007
Publication date:
March 20, 2008
Applicant:
AVENTIS PHARMA DEUTSCHLAND GMBH
Inventors:
Eugen UHLMANN, Gerhard Breipohl, David Will
Abstract: An assay for determining the ability of an enzyme, functional fragment, or functional derivative thereof to modify the phosphorylation status of a biotinylated polypeptide.
Type:
Application
Filed:
May 19, 2004
Publication date:
January 24, 2008
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Norbert Tennagels, Aimo Kannt, Harald Thuering
Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: in which X, R1, R1a, R2, R3, R4 and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate “cGMP” and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.
Type:
Grant
Filed:
April 13, 2005
Date of Patent:
November 27, 2007
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Ursula Schindler, Karl Schönafinger, Hartmut Strobel
Abstract: The present invention provides a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels, and the use of this process.
Type:
Application
Filed:
March 24, 2005
Publication date:
October 4, 2007
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Hans-Willi Jansen, Andrea Bruggemann, Holger Heitsch, Heinz Gogelein
Abstract: The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
Type:
Grant
Filed:
April 24, 2002
Date of Patent:
July 10, 2007
Assignee:
sanofi-aventis Pharma Deutschland GmbH
Inventors:
Cenek Kolar, Jörg Czech, Klaus Bosslet, Gerhard Seemann, Hans-Harald Sedlacek
Abstract: A cyclohexapeptide compound of general formula (I), wherein R1 is C1–C20 alkyl; C9–C20 alkenyl; C9–C20 alkoxyphenyl; an aryl group selected from: phenyl, biphenyl, terphenyl and naphthyl; C1–C12 alkylphenyl, C2–C12 alkenylphenyl, C1–C12 alkoxyphenyl; linoleoyl; palmitoyl; 12-methylmyristoyl; 10,12-dimethylmyristoyl; or —COC6H4(p)OC8H17, R1 and R3 are independently —OH; —CN; —CH2NH2; —N3; aryl; substituted aryl; heterocyclyl and substituted heterocyclic with 1–3 of the same or different heteroatoms; aminoalkylamino; mono or di-substituted linear or cyclic aminoalkylamino; —OR, wherein, R is C1–C12 alkyl; substituted alkyl of the type —(CH2)n—X, where n is 1–5 and X is Cl, Br, I, COOY, CN, NH2 or a heterocyclic and where Y is C1–C6 linear or branched alkyl; C2–C12-alkenyl; aryl; fused aryl; substituted aryl; a heterocyclic containing 1–3 heteroatoms; mono or di-substituted aminoalkyl; or a hydroxy protecting group; and R3 may additionally be imidazolyl; R2 and R4 are independently —H or —OH; R5 is —H or —CH3, R
Type:
Grant
Filed:
July 15, 2000
Date of Patent:
January 23, 2007
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Bansi Lal, Vitthal G. Gund, Ashok K. Gangopadhyay
Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.
Abstract: N-Benzoylureidocinnamic acid derivatives, processes for preparing them and their use The invention relates to N-benzoylureidocinnamic acid derivatives and to their physiologically tolerated salts and physiologically functional derivatives. The invention thus relates to compounds of formula I, in which the radicals have the given meanings, and to their physiologically tolerated salts and processes for preparing them. The compounds are, for example, suitable for use as antidiabetic agents.
Type:
Grant
Filed:
June 6, 2003
Date of Patent:
May 23, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Karl Schoenafinger, Elisabeth Defossa, Dieter Kadereit, Erich Von Roedern, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt
Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
Type:
Grant
Filed:
September 22, 2003
Date of Patent:
May 16, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Abstract: A pharmaceutical preparation comprising a hydrophilic gel-forming agent, water and a compound of the formula I is suitable for the treatment and prophylaxis of dermatomycoses.
Type:
Grant
Filed:
October 23, 2003
Date of Patent:
April 11, 2006
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Manfred Bohn, Karl Theodor Kraemer, Astrid Markus